Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Lymphoma, B-Cell 2Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1HIV Infections 1Enteropathy-Associated T-Cell Lymphoma 1Cranial Nerve Diseases 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Azacitidine 26venetoclax 12Peripheral Blood Stem Cell Transplantation 12fludarabine phosphate 10Mycophenolic Acid 9Whole-Body Irradiation 8Cyclosporine 8Cytarabine 7Cyclophosphamide 6Filgrastim 5Decitabine 5Busulfan 5Methotrexate 4fludarabine 3aldesleukin 3Tacrolimus 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Biopsy 3tipifarnib 2tagraxofusp 2ruxolitinib 2quizartinib 2eprenetapopt 2axatilimab 2X-Rays 2Transplantation 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Chronic × deltacortene × Clear all
NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
17 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡